The Medical Letter on Drugs and Therapeutics
- Peanut Allergen Powder (Palforzia)
- Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
- Consensi - A Fixed-Dose Combination of Amlodipine and Celecoxib
- Addendum: Brolucizumab (Beovu) for Age-Related Macular Degeneration
- Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
Peanut Allergen Powder (Palforzia)
March 9, 2020 (Issue: 1593)The FDA has approved peanut allergen powder-dnfp (Palforzia – Aimmune) for use as oral immunotherapy to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients with a confirmed peanut allergy. It is...more
- CDC. Voluntary guidelines for managing food allergies in schools and early care and education programs. 2013. Available at: http://bit.ly/39Y4H5O. Accessed February 27, 2020.
- G Du Toit et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med 2015; 372:803.
- RL Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients. J Allergy Clin Immune Pract 2019; 7:418.
- PALISADE Group of Clinical Investigators et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med 2018; 379:1991.
- List price according to the manufacturer.
- M Shaker and M Greenhawt. Estimation of health and economic benefits of commercial peanut immunotherapy products: a cost-effectiveness analysis. JAMA Netw Open 2019; 2:e193242.
- Institute for Clinical and Economic Review. Oral immunotherapy and Viaskin® Peanut for peanut allergy: effectiveness and value. 2019. Available at: http://bit.ly/37h4NUu. Accessed February 27, 2020.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.